Tech Transfer eNews Blog
University-Industry Engagement Advisor

U of Washington licenses cannabinoid-based cancer treatment to Pascal Biosciences

By Jesse Schwartz
Published: November 7th, 2018

The University of Washington (UW) and drug developer Pascal Biosciences have entered into an exclusive licensing agreement to commercialize a cannabinoid-based cancer treatment.

The agreement is focused on the lead therapeutic ST-403, which targets glioblastoma multiform and brain metastases and was developed in the lab of renowned UW cannabis researcher Nephi Stella. The therapeutic utilizes a unique mechanism of action to kill cancer cells that may enhance current chemotherapy methods.

Pascal Biosciences plans to launch human clinical studies of ST-403 in 2019.

“I’m excited to have Pascal advancing this promising program and, furthermore, I am honored to help with the future development of Pascal’s broad immune-oncology program, as I believe cannabinoid-based compounds have great potential when combined with checkpoint inhibitors,” says Stella.

Patrick Gray, CEO of Pascal, comments, “ST-403 is a very promising therapeutic candidate that is an ideal fit with our cannabinoid immune activation program that we announced in February. Both programs have great potential in treating cancer, and we are fortunate to have access to and support from Dr. Stella to help facilitate the advancement of this great science into meaningful therapeutics for cancer.”

Source: AP News

The International Survey of Research University Leadership: View of Technology Transfer and Sponsored Research Offices includes 70 pages of in-depth commentary and analysis based on extensive surveying of 53 colleges and universities. It offers a rich set of benchmarks and data to compare against your own university’s technology transfer and sponsored research efforts. For complete details, CLICK HERE >>

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment